The Impact of Effective Therapy With Atorvastatin on the Dynamics of Parameters of Electrical Instability in Patients with ST-Elevation Myocardial Infarction

Aim. To assess the dynamics of parameters of myocardial electrical instability in patients with ST-elevation (STE) myocardial infarction (MI) treated with various doses of atorvastatin. Materials and methods. Patients with STEMI (n=70), who received atorvastatin 20 or 80 mg/day for 48 weeks, were divided into two groups: group “Е” - 38 patients (54.3%) in whom by 48-th week target values of low density lipoprotein cholesterol (LDLC) were achieved, and group “NE” - 32 patients (45.7%) in whom these levels were not achieved. On days 7-9, at 24^th and 48^th weeks after onset of MI the patients underwent 24-hour 12-leads ECG monitoring with subsequent analysis of parameters of myocardial electrical inhomogeneity: late ventricular potentials (LVP), dispersion of QT-interval duration, heart rate variability (HRV) and turbulence. Results. After of treatment with atorvastatin target value of LDLC was achieved in 73.5 and 36.1% of patients receiving 80 and 20 mg/day, respectively. In the group “E” we observed positive dynamics of LVP parameters (QRSf - p<0.01, HFLA - p<0.001, RMS - p<0.05), decreases of QTa disp (p<0.05) and sdQTa (p<0.01), favorable transformation of HRV temporal (SDNNi, pNN50 - p<0.05, RMSSD, TINN - p<0.01) and frequency indices (Hfp, L/H -p<0.001). Most striking evolution in this group referred to HRV during night hours. Conclusion. Atorvastatin induced achievement of target LDLC values decreased myocardial arrhythmic readiness what was reflected by reduction of frequency of LVP registration and dispersion of QT duration, increase of activity of the parasympathetic link of vegetative regulation of cardiac activity.

аторвастатин, инфаркт миокарда, поздние потенциалы, турбулентность, вариабельность ритма сердца, интервал QT, atorvastatin, myocardial infarction, late potentials, turbulence, heart rate variability, Q_T

1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V. пересмотр. Москва, 2012

2. Оганов Р. Г., Бузиашвили Ю. И., Кухарчук В. В. и соавт. Заключение Совета экспертов ВНОК, НОА, РосОКР, НАБИ. Оптимизация терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска. Кардиосоматика 2011;4:80-86

3. Nicholls S.J., Tuzcu E. M., Sipahi I. et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J. Cardiol 2006;97 (11):1553-1557.

4. Nissen S., Nicholls S., Sipahy I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006;195 (13):1556-1565.

5. Nicholls S.J., Ballantyne C. M., Barter Ph.J. et al. Effect of two intensive statin regimens on progression of coronary disease. N. Engl J. Med 2011;330:2078-2087.

6. Аронов Д. М., Бубнова М. Г. Плейотропные эффекты статинов на современном этапе их изучения (фокус на аторвастатин). Кардиосоматика 2012;36:3-5

7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклеро за. Российские рекомендации, 5 пересмотр. Москва, 2012 г.

8. Ridker P. M., Morrow D. A., Rose L. M. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol №70 mg/dl and C-reactive protein №2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J. Am Coll Cardiol 2005;45 (10):1644-1648.

9. Кардиоваскулярная профилактика. Национальные рекомендации. Комитет экс пертов ВНОК. Кардиоваскулярная терапия и профилактика 2011;10 (6):Приложение 2

10. Макаров Л. М., Комолятова В. Н., Куприянова О. О. и др. Национальные российские рекомендации по применению методики холтеровского мониторирования в клинической практике. Российский кардиологический журнал 2014;2 (106):6-71

11. Rittger H., Hochadel M., Behrens S. et al. Age-related differences in diagnosis, treatment and outcome of acute coronary syndromes: results from the German ALKK registry. EuroIntervention 2012;7 (10):1197-1205.

12. Ryan P., George A., Sanjay K. Statins in Acute Coronary Syndromes: Do the Guidelline Recommendations Match the Evidence? J. Am Coll Cardiol 2009;54 (15):1425-1433.

13. Boytsov S., Logunova N., Khomitskaya Yu. Positive and negative predictors of LDL-C goals achievement in patients at moderate to very high cardiovascular risk on lipid-lowering drug therapy (CEPHEUS II). Poster presented at EuroPrevent congress. Spain, Malaga, 6 April 2017.

14. Pelat M., Dessy C., Massion P. et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprorein E. mice in vivo. Circulation 2003;107:2480-2486.

15. Kayikcioglu M., Can L., Evrengul H., Payzin S., Kultursay H. The effect of statin therapy on ventricular late potentials in a myocardial infarction. Int J. Cardiol 2003;90:63-72.

16. Bavry A. A., Mood G. R., Kumbhani D.J. Long-term benefit of statin therapy initiated during hospitalization for acute coronary syndrome: a systematic review of randomized trials. Am J. Cardiovasc Drugs 2007;7 (2):135-141.

17. Siu C. W., Lau C. P., Tse H. F. Prevention of atrial fibrillation recurrence by statin therapy in patients with atrial fibrillation after successful cardiversion. Am J. Cardiol 2003;92:1343-1345.

18. Kayikcioglu M., Can L., Evrengul H. et al. The effect of statin therapy on ventricular late potentials in a myocardial infarction. Int J. Cardiol 2003;90:63-72.

19. Steinberg J. S., Varma N., Cygankiewicz I. et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiacmonitoring/telemetry. Heart Rhythm 2017;14 (7):55-96.